Skip to main content

Table 3 Observed (Obs) and expected (Exp) numbers of cancer cases and standardised incidence ratios (SIR) with 95% confidence intervals (CI) among male workers at the Kokkola cobalt plant during 1969–2013, by site and duration of employment. Only primary sites with ≥2 observed or expected cancer cases included

From: Cancer incidence among Finnish male cobalt production workers in 1969–2013: a cohort study

Primary site

Employment >1 year

Employment >5 years

Obs

Exp

SIR

95% CI

Obs

Exp

SIR

95% CI

All sites

92

91.9

1.00

0.81–1.22

77

71.6

1.08

0.85–1.34

Tongue

3

0.41

7.39

1.52–21.6

3

0.30

10.0

2.06–29.2

Oesophagus

2

1.15

1.74

0.21–6.28

2

0.89

2.24

0.27–8.08

Stomach

7

3.47

2.01

0.81–4.15

5

2.73

1.83

0.59–4.26

Colon

4

4.36

0.92

0.25–2.34

4

3.46

1.16

0.32–2.96

Rectum, rectosigmoid

4

3.80

1.05

0.29–2.69

3

2.93

1.03

0.21–2.99

Pancreas

2

3.44

0.58

0.07–2.09

1

2.69

0.37

0.01–2.07

Larynx, epiglottis

2

0.81

2.45

0.30–8.86

2

0.65

3.09

0.37–11.2

Lung, trachea

6

12.0

0.50

0.18–1.08

5

9.55

0.52

0.17–1.22

Melanoma of the skin

1

3.29

0.30

0.01–1.69

1

2.53

0.39

0.01–2.20

Skin, non-melanoma

3

2.78

1.08

0.22–3.15

3

2.22

1.35

0.28–3.94

Basal cell carcinoma of the skin

18

19.2

0.94

0.56–1.48

12

15.1

0.80

0.41–1.38

Prostate

33

24.4

1.35

0.93–1.89

26

19.4

1.34

0.87–1.96

Kidney

2

3.81

0.52

0.06–1.89

2

3.00

0.67

0.08–2.40

Bladder and urinary tract

9

4.79

1.88

0.86–3.56

6

3.76

1.60

0.59–3.47

Brain, central nervous system

2

2.82

0.71

0.09–2.56

2

2.07

0.97

0.12–3.49

Thyroid gland

2

0.99

2.01

0.24–7.26

2

0.72

2.78

0.34–10.0

Non-Hodgkin lymphoma

3

4.44

0.68

0.14–1.97

3

3.42

0.88

0.18–2.56

Leukaemia

3

2.11

1.42

0.29–4.15

3

1.58

1.90

0.39–5.54